Occical Therapeutics

OcciCal Therapeutics aims to develop the first preventive treatment for diaphragmatic dysfunction induced by mechanical ventilation. This pathology affects more than 14 million of the 20 million people who use mechanical ventilation each year worldwide. This orphan disease, described in 2004, was until then poorly known and had no treatment. Unfortunately, Covid-19 has brought this pathology to light. The objective of the project is to set up a clinical trial with a patented molecule, validated by a solid proof of concept in mice and pigs and patient-derived cells. This is with the aim of reducing the consequences associated with this pathology, namely reducing the prolongation of stay in intensive care, improving the quality of life of patients, reducing the mortality rate and reducing health costs, which are estimated at more than 200 billion euros each year and around the world.